Close Menu

irritable bowel syndrome

Norwegian molecular diagnostics firm Genetic Analysis announced two new developments last week. The first was the appointment of Kari Stenerson, a former Axis-Shield marketing director, as its new CEO.

Researchers led by a group at Beth Israel Deaconess Medical Center have identified a genetic marker associated with the placebo effect in patients with irritable bowel syndrome.

The exclusive sales and marketing agreement covers gene expression tests for inflammatory bowel disease and irritable bowel syndrome.

The first version of the sequencer, about to enter beta-testing, will cost around $250,000 and will be able to generate several gigabases of data in a 5.5-hour run with $250 in consumables costs per gigabase. That price is expected to fall to as little as $2 with later generations.

Tech Transfer Tidbits

Premium

Battelle Ventures, MIT, Hepragen, Wayne State University, Defyrus, UK Ministry of Defence, Columbia U, Intelligent Bio-Systems, Kauffman Foundation

Short Reads

Premium

Intelligent Bio-Systems, Norwich Ventures, National Human Genome Research Institute, Floragenex, National Center for Genome Resources, Decode Genetics, DNAStar, Infogen

IBS has kept a relatively low profile the past couple of years, but it plans to get prototype sequencing systems into the hands of early-access customers as early as the first quartyer of this year.

Pages

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.